GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:
| Conference: | Citizens Life Sciences Conference |
| Date/Time: | Wednesday, May 7, 2025, at 9:30 a.m. EDT |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Jason Spark
Inizio Evoke, Biotech
Phone: 619-849-6005
This email address is being protected from spambots. You need JavaScript enabled to view it.
This press release was published by a CLEAR® Verified individual.
| Last Trade: | US$5.71 |
| Daily Change: | 0.54 10.44 |
| Daily Volume: | 2,417,038 |
| Market Cap: | US$405.740M |
February 27, 2025 February 25, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
